BridgeBio falls, despite new Phase III data for acoramidis

Notwithstanding what it called “positive” late-stage trials with its acoramidis over the weekend, BridgeBio Pharma (Nasdaq: BBIO) saw its shares fall almost 4.5% to $28.36 in early trading on Monday.

BridgeBio announced the presentation of detailed positive results from its Phase III ATTRibute-CM study of acoramidis for patients with ATTR-CM by Dr Julian Gillmore, in a Hot Line session at the European Society of Cardiology Congress 2023.

In July, BridgeBio announced positive top-line results from ATTRibute-CM, which was designed to study the efficacy and safety of acoramidis, an investigational, next-generation, orally-administered, highly potent small molecule stabilizer of transthyretin (TTR).  That new sent the firm’s stock rocketing 66% to $30.30